Last reviewed · How we verify
Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet
Approved treatments
- Lopid · Pfizer Inc.
Clinical guidelines
- FDA label — adj
Gemfibrozil is indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (Type IV hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. - FDA label — adj
Gemfibrozil is indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (Type V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. - FDA label — adj
Gemfibrozil is indicated as adjunctive therapy to diet for reducing the risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet treatment landscape brief
- Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet treatment updates RSS
Frequently asked questions about Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet
What drugs treat Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet?
Tracked treatments include Lopid.
What is the treatment for Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet?
Standard treatment for Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet includes Lopid. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet?
FDA label publishes guidelines for Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet. 3 guideline references tracked.
Related
- Treatment landscape: Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet patent cliff · Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet CI report
- Treatment: Lopid · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing